GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Polaryx Therapeutics, Inc. Common Stock PLYX · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.94

+7.78%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Polaryx Therapeutics, Inc. Common Stock

From its filings with the US Securities and Exchange Commission

SEC filings

Polaryx Therapeutics, Inc. Common Stock is based in Paramus, New Jersey and is incorporated in Wyoming. Its shares trade on Nasdaq under the ticker PLYX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $9.0m. At that date it held total assets of $5.2m and shareholders' equity of $4.6m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
2 Feb 2026
Website
polaryx.com ↗
Head office
140 EAST RIDGEWOOD AVENUE, PARAMUS, NJ, 07652
Incorporated in
WY
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Polaryx Therapeutics' PLX-100 is a preclinical stage orally administrable combination therapy for rare diseases.
  • PLX-200 is a repurposed oral small molecule targeting lysosomal storage disorders in the US market.
  • The company's pipeline includes four distinct therapies, including PLX-400 gene therapy candidate.

Weaknesses

  • PLX-100 and PLX-300 are in preclinical stages, requiring further development.
  • PLX-200 is a repurposed drug, potentially facing regulatory hurdles in the US.
  • The company's focus on rare diseases limits market size compared to broader therapies.

Opportunities

  • PLX-400 gene therapy candidate could address unmet needs in lysosomal storage disorders.
  • US market offers opportunities for rare disease therapies with high unmet demand.
  • Repurposed drugs like PLX-200 may accelerate development timelines in the US.

Threats

  • Regulatory challenges for preclinical therapies like PLX-100 and PLX-300 in the US.
  • Competition from established rare disease therapies in the US market.
  • Limited market size for rare disease treatments compared to common conditions.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.